|
Elotuzumab Clinical Trials
7 actively recruiting trials across 7 locations
▼ -1 trial since July 2026
Also known as: BMS 901608, BMS-901608, BMS901608, Empliciti, Empliciti® +5 more
Pipeline
Phase 3: 4Phase 1/2: 3
Top Sponsors
- Regeneron Pharmaceuticals1
- Pfizer1
- Omar Nadeem, MD1
- Mayo Clinic1
- Karyopharm Therapeutics Inc1
Indications
- Cancer7
- Multiple Myeloma5
- Relapsed Refractory Multiple Myeloma (RRMM)1
- Recurrent Multiple Myeloma1
- Myeloma1
Birmingham, Alabama1 trial
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
University of Alabama at Birmingham - Main /ID# 261434
Phase 3
Mobile, Alabama1 trial
Gilbert, Arizona1 trial
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Banner MD Anderson Cancer Center
Phase 1/2
Duarte, California1 trial
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
City of Hope National Medical Center
Phase 3
Los Angeles, California1 trial
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
University of California Los Angeles (UCLA)
Phase 3
Boston, Massachusetts1 trial
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Brigham and Women's Hospital
Phase 1/2
Rochester, Minnesota1 trial
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic in Rochester
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.